WELCOME TO The government REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Infinidat | December 08, 2020
Infinidat, the market's leading provider of multi-petabyte information storage arrangements, today declared that it has consented to an arrangement to disclose immixGroup its sector distributor, making huge new open doors for value-added resellers (VARs) to develop their business by selling Infinidat's demonstrated storage arrangements into the public authority market.
Under the particulars of the agreement, immixGroup will add Infinidat's storage stage and administrat...
Resecurity | December 17, 2021
Resecurity®, a cybersecurity and intelligence company, today announced the unveiling of their next-generation cybersecurity platform at the 2021 Department of Defense Intelligence Information System (DoDIIS) Worldwide Conference in Pheonix, Arizona. For nearly 20 years, the DoDIIS Worldwide Conference has served as the premier information technology conference welcoming over 2,000 attendees and representing over 400 different government organizations.
Government organizations ...
QOMPLX | September 10, 2020
QOMPLX™, an intelligent decision platform provider, today announced the release of the CMMC Pre-Assessment, a solution to help prepare defense contractors to pass their Cybersecurity Maturity Model Certification (CMMC) audit. The U.S. Department of Defense (DoD) created CMMC to enhance the cybersecurity posture of the companies that make up the Defense Industrial Base (DIB). As part of this upcoming prerequisite, all 300,000+ DIB companies will be required to meet specific maturity levels ...
Johnson & Johnson | August 06, 2020
Johnson & Johnson today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA). The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. De...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE